Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Dec;77(12):1323-8.
doi: 10.1136/jnnp.2006.098079. Epub 2006 Sep 4.

Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies

S A Molloy  1 , E N Rowan, J T O'Brien, I G McKeith, K Wesnes, D J Burn
Affiliations
Clinical Trial

Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies

S A Molloy et al. J Neurol Neurosurg Psychiatry. 2006 Dec.

Abstract

Background: Levodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the cognitive profile of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) is unclear.

Aim: To ascertain the acute and long-term effects of L-dopa on aspects of attention and cognition in patients with DLB and PDD, and to compare these with the effects in Parkinson's disease.

Method: Baseline cognitive and motor function was assessed off L-dopa in patients with Parkinson's disease (n = 22), PDD (n = 27) and DLB (n = 11) using standard "bedside" measures and a computerised programme detecting reaction times and accuracy. All patients then underwent an acute L-dopa challenge with subsequent subjective and objective analysis of alertness, verbal recall, reaction times and accuracy. The same parameters were measured after 3 months on L-dopa to assess the prolonged effect.

Results: Acute L-dopa challenge considerably improved motor function and subjective alertness in all patients without compromising either reaction times or accuracy, but increased fluctuations were noted in both groups with dementia. Neuropsychiatric scores improved in patients with Parkinson's disease both with and without dementia on L-dopa at 3 months. Although patients with Parkinson's disease also had better mean global cognitive function at this time, mean verbal attention and memory deteriorated, and patients with PDD had slower reaction times in some tests. No patient had a marked deterioration over this time. Patients with DLB did not experience any adverse cognitive or neuropsychiatric effects after 3 months of L-dopa treatment.

Conclusion: The use of L-dopa in patients with parkinsonism with dementia does not adversely affect cognitive function.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aarsland D, Andersen K, Larsen J P.et al Risk of dementia in Parkinson's disease: a community based, prospective study. Neurology 200156730–736. - PubMed
    1. Papka M, Rubio A, Schiffer R B. A review of Lewy body disease, an emerging concept of cortical dementia. J Neuropsychiatr Clin Neurosci 199810267–279. - PubMed
    1. Mahieux F, Fenelon G, Flahault A.et al Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 199864178–183. - PMC - PubMed
    1. Ballard C G, Aarsland D, McKeith I G.et al Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002591714–1720. - PubMed
    1. Aarsland D, Ballard C, Larsen J P.et al A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 200116528–536. - PubMed

Publication types